VRAX
Virax Biolabs Group Limited Ordinary Shares
NASDAQ: VRAX · HEALTHCARE · BIOTECHNOLOGY
$0.13
-0.81% today
Updated 2026-04-30
Market cap
$993260.00
P/E ratio
—
P/S ratio
332.64x
EPS (TTM)
$-1.22
Dividend yield
—
52W range
$0 – $1
Volume
15.9M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D6.5
Quality
B2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-4.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$1.00
+646.83%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.10x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -4.33 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-3.06M
- Revenue declining -67.50% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $8561.00 | $156419.00 | $6331.00 | $2986.00 |
| Net income | $-1.71M | $-5.46M | $-6.73M | $-6.06M | $-2.34M |
| EPS | — | — | — | — | $-1.22 |
| Free cash flow | $-809069.00 | $-4.36M | $-7.41M | $-5.17M | $-3.06M |
| Profit margin | — | -63,748.32% | -4,304.81% | -95,739.17% | — |
Peer comparison
Smart narrative
Virax Biolabs Group Limited Ordinary Shares trades at $0.13. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.33, it sits in the distress. TTM revenue stands at $2986.00.
Frequently asked questions
What is Virax Biolabs Group Limited Ordinary Shares's stock price?
Virax Biolabs Group Limited Ordinary Shares (VRAX) trades at $0.13.
Is Virax Biolabs Group Limited Ordinary Shares overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of Virax Biolabs Group Limited Ordinary Shares (VRAX)?
The analyst target price is $1.00, representing +646.8% upside from the current price of $0.13.
What is Virax Biolabs Group Limited Ordinary Shares's revenue?
TTM revenue is $2986.00.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-4.33 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio332.64x
ROE-83.80%
Beta1.60
50D MA$0.18
200D MA$0.46
Shares out0.01B
Float0.01B
Short ratio—
Avg volume15.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—